Vetoquinol SA Logo

Vetoquinol SA

Develops and markets veterinary drugs and products for companion animals and livestock worldwide.

VETO | PA

Overview

Corporate Details

ISIN(s):
FR0004186856
LEI:
969500YP0AETQIK48R39
Country:
France
Address:
Village, 70200 MAGNY-VERNOIS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Vetoquinol SA is an independent, family-owned global company exclusively dedicated to animal health. It specializes in the research, development, production, and marketing of veterinary drugs and non-medicinal products. The company's portfolio primarily serves companion animals, such as dogs and cats, which constitute the majority of its business, alongside livestock, including cattle and pigs. Vetoquinol works in close partnership with veterinarians, who are the main prescribers of its products. With a presence in approximately 100 countries through a network of subsidiaries and distributors, the company focuses on innovation and providing solutions for animal diseases worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-28 17:45
Earnings Release
Quarterly financial reporting / Third quarter financial report
English 273.2 KB
2025-10-28 17:45
Earnings Release
Information financière trimestrielle / Information financière du troisième trim…
French 260.0 KB
2025-09-11 17:45
Earnings Release
Inside Information / News release on accounts, results
English 216.2 KB
2025-09-11 17:45
Interim Report
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier …
French 226.4 KB
2025-09-11 17:45
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 219.1 KB
2025-09-04 15:45
Declaration of Voting Results & Voting Rights Announcements
FORMULAIRE DE DECLARATION D'ACTIONS ET DE DROITS DE VOTE
French 376.1 KB
2025-06-06 14:45
Declaration of Voting Results & Voting Rights Announcements
FORMULAIRE DE DECLARATION D'ACTONS ET DE DROITS DE VOTE
French 374.6 KB
2025-05-05 15:00
Declaration of Voting Results & Voting Rights Announcements
FORMULAIRE DE DECLARATION D'ACTIONS ET DE DROITS DE VOTE
French 372.0 KB
2025-04-25 10:26
Report Publication Announcement
Terms of availability of the information and the report on corporate governance
English 535.3 KB
2025-04-25 10:26
Registration Form
Modalités de mise à disposition de l’information et du rapport sur gouvernement…
French 536.8 KB
2025-04-25 09:58
Earnings Release
Information financière trimestrielle / Information financière du premier trimes…
French 738.5 KB
2025-04-25 09:58
Earnings Release
Quarterly financial reporting / First quarter financial report
English 737.3 KB
2025-04-25 09:45
Registration Form
Information et rapport sur gouvernement d'entreprise
French 12.7 MB
2025-04-24 08:10
Annual Report (ESEF)
DEPOT DEU VETOQUINOL
French 18.6 MB
2025-03-20 17:45
Earnings Release
Inside Information / News release on accounts, results
English 223.5 KB

Automate Your Workflow. Get a real-time feed of all Vetoquinol SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vetoquinol SA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vetoquinol SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-07-25 N/A Other Sell 4,000 399,600.00 EUR
2024-07-25 N/A Other Buy 4,000 399,600.00 EUR
2024-03-21 N/A Other Sell 3,500 346,500.00 EUR
2024-03-21 N/A Other Buy 3,500 346,500.00 EUR
2024-01-03 N/A Other Buy 1,800 182,880.00 EUR
2023-11-16 N/A Other Buy 1,000 87,500.00 EUR
2023-11-13 N/A Other Sell 1,000 87,500.00 EUR
2023-09-08 N/A Other Buy 400 33,960.00 EUR

Peer Companies

Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA
LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB

Talk to a Data Expert

Have a question? We'll get back to you promptly.